April 4, 2005
To: All healthcare providers
Re: Introduction of Meningococcal Conjugate Vaccine
On January 14, 2005, the FDA licensed Menactra, a new meningococcal conjugate vaccine (MCV4). The vaccine is licensed for use in persons 11-55 years of age. Menactra provides protection against the same four strains of Neisseria meningitidis (A, C, Y, W-135) as Menomune, the meningococcal polysaccharide vaccine (PSV4). However, additional benefits of a conjugate vaccine in preventing meningococcal disease include improved duration of protection, induction of immunologic memory, booster responses, and reduction in nasopharyngeal bacterial carriage.
Based on these benefits, the Advisory Committee on Immunization Practices (ACIP), has issued new recommendations for routine vaccination of adolescents 11 through 18 years of age. ACIP recommends vaccinating adolescents:
- At the 11-12 year visit with a primary health care provider
- At high school entry
- Who are incoming college freshmen living in college dormitories
As with all routinely recommended childhood vaccines, the Rhode Island Department of Health (HEALTH) is working with CDC to secure a VFC contract. The vaccine is expected to be available to VFC providers in the near future. The Immunization Program will continue to update you as more information becomes available.
Questions about meningococcal vaccines can be directed to Patricia Raymond, RN at 222-5921 or patr@doh.state.ri.us. |
